Free Trial

Gyre Therapeutics (GYRE) Institutional Ownership

Gyre Therapeutics logo
$8.14 +0.34 (+4.36%)
As of 07/3/2025 03:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Institutional Ownership Changes (13F Filings) for Gyre Therapeutics (NASDAQ:GYRE)

Current
Institutional Ownership
Percentage
23.99%
Number of
Institutional Buyers
(last 12 months)
16
Total
Institutional Inflows
(last 12 months)
$4.91M
Number of
Institutional Sellers
(last 12 months)
4
Total
Institutional Outflows
(last 12 months)
$574.17K
Get GYRE Insider Trade Alerts

Want to know when executives and insiders are buying or selling Gyre Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Skip Chart & View Institutional Buying and Selling Data

GYRE Institutional Buying and Selling by Quarter

Gyre Therapeutics Major Shareholders & Ownership History

Reporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
6/27/2025Goldman Sachs Group Inc.16,147$125K0.0%-38.8%0.017%
5/16/2025Goldman Sachs Group Inc.16,147$125K0.0%-38.8%0.017%
5/14/2025Advantage Alpha Capital Partners LP13,663$105K0.0%+54.0%0.015%
5/13/2025American Century Companies Inc.23,825$184K0.0%N/A0.025%
5/9/2025Charles Schwab Investment Management Inc.111,416$860K0.0%-2.7%0.119%
5/2/2025SBI Securities Co. Ltd.123,629$954K0.0%+22.1%0.132%
4/29/2025Bank of New York Mellon Corp16,492$127K0.0%+18.7%0.018%
4/7/2025GAMMA Investing LLC1,822$140K0.0%+15,083.3%0.002%
2/17/2025Bank of America Corp DE6,937$84K0.0%+40.4%0.007%
2/14/2025Northern Trust Corp103,382$1.25M0.0%+9.1%0.111%
2/13/2025Barclays PLC10,543$128K0.0%+13.5%0.011%
2/13/2025Wells Fargo & Company MN4,016$49K0.0%+29.4%0.004%
2/11/2025Advantage Alpha Capital Partners LP8,873$107K0.0%-66.7%0.009%
2/6/2025Charles Schwab Investment Management Inc.114,566$1.39M0.0%+0.8%0.123%
2/6/2025SBI Securities Co. Ltd.101,239$1.23M0.0%N/A0.108%
2/4/2025Bank of New York Mellon Corp13,896$168K0.0%+11.1%0.015%
11/19/2024Barclays PLC9,288$116K0.0%+281.8%0.010%
11/16/2024Geode Capital Management LLC303,647$3.81M0.0%+16.9%0.325%
11/15/2024Barclays PLC9,288$116K0.0%+281.8%0.010%
11/15/2024State Street Corp104,490$1.31M0.0%+8.8%0.112%
11/13/2024FMR LLC3,742$47K0.0%N/A0.004%
11/13/2024Advantage Alpha Capital Partners LP26,634$334K0.1%N/A0.029%
11/12/2024Charles Schwab Investment Management Inc.113,648$1.43M0.0%+392.2%0.122%
8/14/2024Marshall Wace LLP10,720$128K0.0%-58.0%0.013%
8/9/2024Renaissance Technologies LLC13,900$166K0.0%N/A0.016%
8/9/2024WINTON GROUP Ltd18,467$220K0.0%N/A0.022%
8/1/2024Rhumbline Advisers10,291$123K0.0%N/A0.012%
7/26/2024Bank of New York Mellon Corp18,266$218K0.0%N/A0.021%
5/10/2024Vanguard Group Inc.195,098$3.41M0.0%-1.5%0.228%
(Data available from 1/1/2016 forward)

GYRE Institutional Ownership - Frequently Asked Questions

Who are the largest shareholders of GYRE shares?

During the previous two years, 19 institutional investors and hedge funds held shares of Gyre Therapeutics. The most heavily invested institutionals were Geode Capital Management LLC ($3.81M), Vanguard Group Inc. ($3.41M), State Street Corp ($1.31M), Northern Trust Corp ($1.25M), SBI Securities Co. Ltd. ($954K), Charles Schwab Investment Management Inc. ($860K), and WINTON GROUP Ltd ($220K).Learn more on Gyre Therapeutics' institutional investors.

What percentage of Gyre Therapeutics' stock is owned by institutional investors?

23.99% of Gyre Therapeutics' stock is owned by institutional investors. Learn more on GYRE's institutional investor holdings.

Which institutional investors have been buying Gyre Therapeutics' stock?

Of the 16 institutional investors that purchased Gyre Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: SBI Securities Co. Ltd. ($123.63K), Charles Schwab Investment Management Inc. ($91.48K), Geode Capital Management LLC ($43.84K), Advantage Alpha Capital Partners LP ($31.42K), American Century Companies Inc. ($23.83K), Bank of New York Mellon Corp ($22.25K), and WINTON GROUP Ltd ($18.47K).

How much institutional buying is happening at Gyre Therapeutics?

Institutional investors have bought a total of 419,564 shares in the last 24 months. This purchase volume represents approximately $4.91M in transactions.

Which of Gyre Therapeutics' major shareholders have been selling company stock?

The following institutional investors have sold Gyre Therapeutics stock in the last 24 months: Goldman Sachs Group Inc. ($20.48K), Advantage Alpha Capital Partners LP ($17.76K), Marshall Wace LLP ($14.82K), and Charles Schwab Investment Management Inc. ($3.15K).

How much institutional selling is happening at Gyre Therapeutics?

Institutional investors have sold a total of 56,213 shares in the last 24 months. This volume of shares sold represents approximately $574.17K in transactions.



This page (NASDAQ:GYRE) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners